Bryn Mawr Capital Management Inc’s Quest Diagnostics DGX Stock Holding History

Bryn Mawr Capital Management Inc’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-40,704	Closed	-$2.5M	–	86
2015 Q3	$2.5M	Buy	+40,704	New	+$2.85M	0.43%	78
2014 Q3	–	Sell	-66,300	Closed	-$3.89M	–	573
2014 Q2	$3.89M	Buy	66,300 +24,135	+57%	+$1.41M	0.37%	84
2014 Q1	$2.44M	Buy	+42,165	New	+$2.26M	0.22%	148
2013 Q3	–	Sell	-97,674	Closed	-$5.92M	–	555
2013 Q2	$5.92M	Buy	+97,674	New	+$5.82M	0.4%	92

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bryn Mawr Capital Management Inc's DGX Position: Q4 2015 in Review

Bryn Mawr Capital Management Inc sold out of Quest Diagnostics (DGX) in Q4 2015, closing a stake of 40,704 shares — an estimated $2.5M sold.

Bryn Mawr Capital Management Inc first reported a position in DGX in Q2 2013 and held it in 4 quarters. The position peaked at $5.92M in Q2 2013. 535 funds tracked by Wall St. Rank hold DGX as of Q4 2015.

Bryn Mawr Capital Management Inc reported no remaining Quest Diagnostics position as of Q4 2015 after selling out during the quarter.
Bryn Mawr Capital Management Inc sold 40,704 Quest Diagnostics shares in Q4 2015, an estimated $2.5M.
Bryn Mawr Capital Management Inc first reported a position in Quest Diagnostics in Q2 2013 and held it in 4 quarters.
Bryn Mawr Capital Management Inc's Quest Diagnostics position peaked at $5.92M in Q2 2013.
535 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2015.

Based on Bryn Mawr Capital Management Inc's 13F filing for Q4 2015.